Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.55 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.55 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.55 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.55 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.55 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.55 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.55 |
| ▸ | GOT1 | P17174 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23246046 | 0.98 | POLB (0.66) | POLBNAMPTMAPTTRPV1CNR1 | |
| SCHEMBL3072567 | 0.94 | MAPT (0.59) | POLBNAMPTMAPTTRPV1CNR1 | |
| Hydrochloric Acid SCHEMBL28861578 | 0.92 | POLB (0.58) | POLBNAMPTMAPTTRPV1CNR1 | |
| SCHEMBL14306236 | 0.86 | MAPT (0.69) | NAMPTMAPTTRPV1CNR1CNR2 | |
| SCHEMBL4559682 | 0.86 | MAPT (0.73) | NAMPTMAPTTRPV1CNR1CNR2 | |
| SCHEMBL2385073 | 0.85 | POLB (0.55) | POLBMAPTHPGDS | |
| SCHEMBL30965820 | 0.85 | POLB (0.63) | POLBTRPV1CNR1CNR2 | |
| SCHEMBL6153200 | 0.84 | KMT2A (0.69) | NAMPTMAPTTRPV1CNR1CNR2 | |
| SCHEMBL2384223 | 0.83 | POLB (0.61) | POLBMAPTTRPV1FAAHGOT1 | |
| SCHEMBL2054569 | 0.83 | KMT2A (0.71) | POLBMAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221633-A | TRPV1/URAT1 dual inhibitor, preparation method and application thereof | 郑州大学第一附属医院 | 2024-06-21 | — | — | CN | claimed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | claimed |
| EP-2616077-B1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | UNIV LEUVEN KATH (BE) | 2016-08-31 | — | — | EP | claimed |
| US-9193741-B2 | Antiviral activity of bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K. U. LEUVEN R&D (BE) | 2015-11-24 | — | — | US | claimed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | claimed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | claimed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | claimed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | claimed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | claimed |
| EP-2575969-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-04-10 | — | — | EP | claimed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | claimed |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-02-23 | — | — | US | claimed |
| EP-2405973-A2 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-01-18 | — | — | EP | claimed |
| WO-2011147753-A1 | ANTIVIRAL ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2011-12-01 | — | — | WO | claimed |
| WO-2010103130-A2 | NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-09-16 | — | — | WO | claimed |
| EP-4678234-A1 | ANTAGONIST HETEROCYCLIC COMPOUNDS INVOLVED IN THE CGAS-STING ROUTE | Centre National de la Recherche Scientifique (FR) | 2026-01-14 | — | — | EP | disclosed |
| CN-118221633-A | TRPV1/URAT1 dual inhibitor, preparation method and application thereof | 郑州大学第一附属医院 | 2024-06-21 | — | — | CN | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099156-A1 | Heterocyclic Compounds as Ccr2b antagonists | CCR2, CCR3, CXCR2 | POLB 1540/4885NAMPT 1465/4885MAPT 4643/4885 |
| US-20120046278-A1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | TPMT, STAT6, IL4 | POLB 4372/4885NAMPT 1272/4885MAPT 3520/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | POLB 1389/4885NAMPT 3716/4885MAPT 4213/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | POLB 870/4885NAMPT 2950/4885MAPT 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.